Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025

The global anticoagulants market size is expected to reach USD 47.10 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Heparin segment is projected to experience significant growth over the forecast period.
Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030.
The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period.
North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. Asia Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.

Product Code: GVR-4-68040-191-0

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug category
- 1.2.2. Route of administration
- 1.2.3. Application
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Drug category outlook
- 2.2.2. Route of administration outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Anticoagulants Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

4.1. Drug Category Segment Dashboard
4.2. Anticoagulants Market: Drug Category Movement Analysis
4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2018 to 2030 (USD Million)
4.4. Novel Oral Anticoagulants (NOACs)
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Eliquis
  - 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Xarelto
  - 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Savaysa & lixiana
  - 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.5. Pradaxa
  - 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Vitamin K Antagonist
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Direct Thrombin Inhibitors
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Heparin
- 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7.2. Type
  - 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.2.2. Low Molecular Weight Heparin
    - 4.7.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.2.3. Ultra-low Molecular Weight Heparin
    - 4.7.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.2.4. Unfractionated Heparin
    - 4.7.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7.3. Source
  - 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.3.2. Porcine
    - 4.7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.3.3. Bovine
    - 4.7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 4.7.3.4. Others
    - 4.7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

5.1. Route of Administration Segment Dashboard
5.2. Anticoagulants Market: Route of Administration Movement Analysis
5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Oral Anticoagulants
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Injectable Anticoagulants
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

6.1. Application Segment Dashboard
6.2. Anticoagulants Market: Application Movement Analysis
6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- 6.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.5. Deep Vein Thrombosis (DVT)
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.6. Pulmonary Embolism
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.7. Other Applications
- 6.7.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing market by Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. UK
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. China
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework/ reimbursement structure
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework/ reimbursement structure
  - 7.6.4.3. Competitive scenario
  - 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework/ reimbursement structure
  - 7.6.5.3. Competitive scenario
  - 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.8. MEA
- 7.8.1. South Africa
  - 7.8.1.1. Key country dynamics
  - 7.8.1.2. Regulatory framework/ reimbursement structure
  - 7.8.1.3. Competitive scenario
  - 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework/ reimbursement structure
  - 7.8.2.3. Competitive scenario
  - 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework/ reimbursement structure
  - 7.8.3.3. Competitive scenario
  - 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Regulatory framework/ reimbursement structure
  - 7.8.4.3. Competitive scenario
  - 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
- 8.4.1. Aspen Holdings
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Pfizer Inc.
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. Bristol-Myers Squibb Company
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. GSK plc
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. Sanofi
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. Bayer AG
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. Boehringer Ingelheim International GmbH
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Johnson & Johnson Services, Inc.
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. Eisai Co., Ltd.
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Product benchmarking
  - 8.4.10.4. Strategic initiatives

Product Code: GVR-4-68040-191-0

List of Tables

Table 1 List of abbreviations
Table 2 Global anticoagulants market, by region, 2018 - 2030 (USD Million)
Table 3 Global anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 4 Global anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 5 Global anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 6 North America anticoagulants market, by country, 2018 - 2030 (USD Million)
Table 7 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 8 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 9 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 10 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 11 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 12 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 13 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 14 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 15 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 16 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 17 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 18 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 19 Europe anticoagulants market, by country, 2018 - 2030 (USD Million)
Table 20 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 21 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 22 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 23 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 24 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 25 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 26 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 27 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 28 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 29 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 30 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 31 France anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 32 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 33 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 34 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 35 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 36 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 37 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 38 Asia Pacific anticoagulants market, by country, 2018 - 2030 (USD Million)
Table 39 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 40 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 41 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 42 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 43 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 44 China anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 45 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 46 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 47 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 48 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 49 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 50 India anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 51 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 52 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 53 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 54 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 55 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 56 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 57 Latin America anticoagulants market, by country, 2018 - 2030 (USD Million)
Table 58 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 59 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 60 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 61 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 62 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 63 Brazil surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 64 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 65 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 66 Argentina surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 67 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
Table 68 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 69 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 70 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 71 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 72 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 73 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 74 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 75 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 76 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 77 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 78 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 79 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
Table 80 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
Table 81 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
Table 82 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Anticoagulants market: market outlook
Fig. 10 Anticoagulants competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Anticoagulants market driver impact
Fig. 16 Anticoagulants market restraint impact
Fig. 17 Anticoagulants market strategic initiatives analysis
Fig. 18 Anticoagulants market: Drug category movement analysis
Fig. 19 Anticoagulants market: Drug category outlook and key takeaways
Fig. 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
Fig. 21 Eliquis market estimates and forecast, 2018 - 2030
Fig. 22 Xarelto market estimates and forecast, 2018 - 2030
Fig. 23 Savaysa & lixiana market estimates and forecast, 2018 - 2030
Fig. 24 Pradaxa market estimates and forecast, 2018 - 2030
Fig. 25 Vitamin K Antagonist market estimates and forecast, 2018 - 2030
Fig. 26 Direct Thrombin Inhibitors market estimates and forecast, 2018 - 2030
Fig. 27 Heparin market estimates and forecast, 2018 - 2030
Fig. 28 Low molecular weight heparin market estimates and forecast, 2018 - 2030
Fig. 29 Ultra-low molecular weight heparin market estimates and forecast, 2018 - 2030
Fig. 30 Unrationed heparin market estimates and forecast, 2018 - 2030
Fig. 31 Heparin sources market estimates and forecast, 2018 - 2030
Fig. 32 Porcine-based heparin market estimates and forecast, 2018 - 2030
Fig. 33 Bovine-based heparin market estimates and forecast, 2018 - 2030
Fig. 34 Other heparin market estimates and forecast, 2018 - 2030
Fig. 35 Others market estimates and forecast, 2018 - 2030
Fig. 36 Anticoagulants Market: Route of administration movement Analysis
Fig. 37 Anticoagulants market: Route of administration outlook and key takeaways
Fig. 38 Oral anticoagulants market estimates and forecasts, 2018 - 2030
Fig. 39 Injectable anticoagulants market estimates and forecasts,2018 - 2030
Fig. 40 Anticoagulants market: Application movement analysis
Fig. 41 Anticoagulants market: Application outlook and key takeaways
Fig. 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2018 - 2030
Fig. 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
Fig. 44 Pulmonary embolism market estimates and forecasts, 2018 - 2030
Fig. 45 Other applications market estimates and forecasts,2018 - 2030
Fig. 46 Global anticoagulants market: Regional movement analysis
Fig. 47 Global anticoagulants market: Regional outlook and key takeaways
Fig. 48 North America market estimates and forecasts, 2018 - 2030
Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
Fig. 50 Canada market estimates and forecasts, 2018 - 2030
Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
Fig. 52 Europe market estimates and forecasts, 2018 - 2030
Fig. 53 UK market estimates and forecasts, 2018 - 2030
Fig. 54 Germany market estimates and forecasts, 2018 - 2030
Fig. 55 France market estimates and forecasts, 2018 - 2030
Fig. 56 Italy market estimates and forecasts, 2018 - 2030
Fig. 57 Spain market estimates and forecasts, 2018 - 2030
Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 59 China market estimates and forecasts, 2018 - 2030
Fig. 60 Japan market estimates and forecasts, 2018 - 2030
Fig. 61 India market estimates and forecasts, 2018 - 2030
Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
Fig. 63 Australia market estimates and forecasts, 2018 - 2030
Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 70 UAE market estimates and forecasts, 2018 - 2030
Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030

Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

Description

Table of Contents

List of Tables

Anticoagulants Market Growth & Trends:

Anticoagulants Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Anticoagulants Market Variables, Trends & Scope

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures